Most relevant adverse events during induction and consolidations
| Adverse event . | Induction . | Consolidations . | ||
|---|---|---|---|---|
| All grades, % . | Grade 3 or 4, % . | All grades, % . | Grade 3 or 4, % . | |
| Low fibrinogen | 61.1 | 44.2 | 43.9 | 15.8 |
| Liver toxicity (all) | 51.6 | 22.1 | 53.7 | 20.0 |
| Transaminase elevation | 37.8 | 14.7 | 20 | 4.2 |
| Bilirubin elevation | 36.8 | 21.1 | 44.2 | 18.9 |
| Hyperglycemia | 43.7 | 14.7 | 25 | 5.3 |
| Hypertrigliceridemia | 34.7 | 5.3 | 54.3 | 14.7 |
| Neuropathy | 13.7 | 6.3 | 24.4 | 1.1 |
| Thrombosis | 10.5 | 2.1 | 6.1 | 2.1 |
| Hypersensitivity | 2.1 | 1.1 | 3.7 | 3.7 |
| Pancreatitis | 2.1 | 2.1 | 2.4 | 1.1 |
| Adverse event . | Induction . | Consolidations . | ||
|---|---|---|---|---|
| All grades, % . | Grade 3 or 4, % . | All grades, % . | Grade 3 or 4, % . | |
| Low fibrinogen | 61.1 | 44.2 | 43.9 | 15.8 |
| Liver toxicity (all) | 51.6 | 22.1 | 53.7 | 20.0 |
| Transaminase elevation | 37.8 | 14.7 | 20 | 4.2 |
| Bilirubin elevation | 36.8 | 21.1 | 44.2 | 18.9 |
| Hyperglycemia | 43.7 | 14.7 | 25 | 5.3 |
| Hypertrigliceridemia | 34.7 | 5.3 | 54.3 | 14.7 |
| Neuropathy | 13.7 | 6.3 | 24.4 | 1.1 |
| Thrombosis | 10.5 | 2.1 | 6.1 | 2.1 |
| Hypersensitivity | 2.1 | 1.1 | 3.7 | 3.7 |
| Pancreatitis | 2.1 | 2.1 | 2.4 | 1.1 |